This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Karim, M Y Articles by Hughes, G R. Search for Related Content PubMed PubMed Citation Articles by Karim, M Y Articles by Hughes, G R. Social Bookmarking                         What's this?

Update on therapy — thalidomide in the treatment of lupus

Lupus Research Unit, Rayne Institute, St Thomas' Hospital, London, UK; Department of Immunology, 2nd Floor, North Wing, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK youskarim{at}aol.com

G Ruiz-Irastorza

M A Khamashta

G RV Hughes

Lupus Research Unit, Rayne Institute, St Thomas' Hospital, London, UK

Thalidomide has been shown to be an effective treatment for cutaneous forms of lupus erythematous refractory to other therapies. Thalidomide has very serious side effects, including teratogenicity and neuropathy, which limit its clinical use in lupus to such severe refractory cases. Efficacy has been confirmed in several studies, although recurrence after discontinuation of treatment is frequent. More recent experience suggests that lower doses than originally used may be effective, which may result in a reduction in side effects. Much effort has been expended in studying the mechanisms of action of thalidomide, although as yet it is unclear which of the mechanisms identified to date contribute to its efficacy in treating cutaneous forms of lupus erythematosus. Identification of patients suitable for thalidomide therapy requires a rigorous selection process. Potential side effects should be clearly explained, particularly teratogenicity as many patients are young women. Written consent and a negative pregnancy test must be obtained prior to commencement of therapy. Reliable contraceptive measures should be strictly observed by patients taking thalidomide. Close clinical and neurophysiological supervision using nerve conduction studies should be undertaken.

Key Words: thalidomide • lupus • cutaneous • neuropathy • teratogenicity

Lupus, Vol. 10, No. 3, 188-192 (2001)
DOI: 10.1191/096120301677213822


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. E. Lampropoulos, S. Sangle, P. Harrison, G. R. V. Hughes, and D. P. D'Cruz Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative Rheumatology, November 1, 2004; 43(11): 1383 - 1385. [Abstract] [Full Text] [PDF]

				C. Briani, G. Zara, R. Rondinone, S. Della Libera, M. Ermani, S. Ruggero, A. Ghirardello, S. Zampieri, and A. Doria Thalidomide neurotoxicity: Prospective study in patients with lupus erythematosus Neurology, June 22, 2004; 62(12): 2288 - 2290. [Abstract] [Full Text] [PDF]

				A Filiotou, G Vaiopoulos, V Capsimali, N Stavrianeas, and A Kaloterakis Acute intermittent porphyria and systemic lupus erythematosus: report of a case and review of the literature Lupus, March 1, 2002; 11(3): 190 - 192. [Abstract] [PDF]

				J-C Piette, A Sbai, and C Frances Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus Lupus, February 1, 2002; 11(2): 67 - 70. [PDF]